Bank of America Securities analyst Dina Ramadane has maintained their bullish stance on VERA stock, giving a Buy rating on November 19.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dina Ramadane has given her Buy rating due to a combination of factors that highlight the potential of Vera Therapeutics’ atacicept in the treatment of IgA nephropathy (IgAN). The recent approval of a competitor’s drug, which targets a broad patient population without stringent requirements, suggests a favorable market environment for atacicept. This broadening of the target market is expected to enhance atacicept’s total addressable market (TAM) at its launch, projected for mid-2026, and aligns with a positive outlook on its market performance.
Furthermore, concerns about anti-drug antibodies (ADAs) seen in a competitor’s product do not appear to affect atacicept. Vera Therapeutics has reported no evidence of neutralizing ADAs impacting atacicept, and its Phase 2 data demonstrates sustained efficacy over two years. These factors contribute to a strong confidence in atacicept’s profile, supporting the Buy rating and a price objective of $48, significantly above the current trading price.
In another report released on November 19, H.C. Wainwright also maintained a Buy rating on the stock with a $90.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VERA in relation to earlier this year.